HK Stock MarketDetailed Quotes
01177 SINO BIOPHARM
- 2.340
- -0.090-3.70%
Market Closed Apr 19 16:08 CST
43.99BMarket Cap17.08P/E (TTM)
2.430High2.290Low133.65MVolume2.400Open2.430Pre Close311.44MTurnover0.71%Turnover Ratio17.08P/E (Static)18.80BShares4.47052wk High1.31P/B43.99BFloat Cap2.29052wk Low0.08Dividend TTM18.80BShs Float10.980Historical High0.120Dividend LFY5.76%Amplitude-0.560Historical Low2.330Avg Price1000Lot Size3.42%Div YieldTTM5.13%Div Yield LFY
SINO BIOPHARM Key Stats
All
YOY
| (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | (Q6)Jun 30, 2019 | (FY)Dec 31, 2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | ---- | -68.89%5.78B | ---- | 270.49%18.57B | ---- | -11.91%5.01B | ---- | -50.21%5.69B | ---- | 172.39%11.43B |
| Profit adjustment | ||||||||||
| Interest (income) - adjustment | ---- | -24.30%-201.44M | ---- | 16.47%-162.06M | ---- | 24.72%-194M | ---- | -58.37%-257.71M | ---- | -95.92%-162.72M |
| Dividend (income)- adjustment | ---- | -495.59%-14.19M | ---- | 47.42%-2.38M | ---- | -16.56%-4.53M | ---- | 68.02%-3.89M | ---- | 57.00%-12.16M |
| Investment loss (gain) | ---- | 24.35%-299.15M | ---- | -22.91%-395.45M | ---- | -9.01%-321.75M | ---- | 23.00%-295.16M | ---- | -44.06%-383.31M |
| Attributable subsidiary (profit) loss | ---- | 101.12%152.98M | ---- | -421,714.29%-13.63B | ---- | 102.90%3.23M | ---- | -85.92%-111.39M | ---- | 85.35%-59.91M |
| Impairment and provisions: | --0 | -96.71%23.33M | --0 | 787.28%708.38M | --0 | 33.00%79.84M | --0 | -8.50%60.03M | --0 | --65.61M |
| -Impairment of property, plant and equipment (reversal) | ---- | ---- | ---- | -72.51%3.75M | ---- | --13.64M | ---- | ---- | ---- | ---- |
| -Impairment of trade receivables (reversal) | ---- | 142.20%3.93M | ---- | --1.62M | ---- | ---- | ---- | ---- | ---- | ---- |
| -Impairment of goodwill | ---- | ---- | ---- | --47.25M | ---- | ---- | ---- | ---- | ---- | ---- |
| -Other impairments and provisions | ---- | -97.04%19.4M | ---- | 890.55%655.75M | ---- | 10.28%66.2M | ---- | -8.50%60.03M | ---- | --65.61M |
| Revaluation surplus: | --0 | 975.91%390.82M | --0 | 106.84%36.33M | --0 | -5,092.93%-531.45M | --0 | -76.27%10.64M | --0 | 158.36%44.85M |
| -Derivative financial instruments fair value (increase) | ---- | 113.03%31.41M | ---- | -173.92%-241.07M | ---- | ---88.01M | ---- | ---- | ---- | ---- |
| -Other fair value changes | ---- | 29.57%359.41M | ---- | 162.56%277.4M | ---- | -4,266.08%-443.44M | ---- | -76.27%10.64M | ---- | 158.36%44.85M |
| Asset sale loss (gain): | --0 | -181.00%-3.47M | --0 | 621.42%4.28M | --0 | 101.00%593K | --0 | 99.10%-59.15M | --0 | -342,691.94%-6.6B |
| -Available for sale investment sale loss (gain) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---73.93M | ---- | ---- |
| -Loss (gain) from sale of subsidiary company | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---6.6B |
| -Loss (gain) on sale of property, machinery and equipment | ---- | -181.00%-3.47M | ---- | 621.42%4.28M | ---- | -95.99%593K | ---- | 338.20%14.79M | ---- | 275.36%3.37M |
| Depreciation and amortization: | --0 | 5.48%1.05B | --0 | -40.02%992.56M | --0 | 14.47%1.65B | --0 | 19.45%1.45B | --0 | 252.44%1.21B |
| -Depreciation | ---- | 4.73%945.3M | ---- | 1.27%902.64M | ---- | 35.30%891.35M | ---- | 36.36%658.79M | ---- | 46.07%483.11M |
| -Amortization of intangible assets | ---- | 13.09%101.69M | ---- | -88.22%89.92M | ---- | -2.97%763.49M | ---- | 8.21%786.83M | ---- | 5,647.47%727.11M |
| Financial expense | ---- | 42.27%439.06M | ---- | -4.56%308.62M | ---- | 40.63%323.37M | ---- | 50.04%229.95M | ---- | 96.63%153.26M |
| Special items | ---- | --39.31M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Operating profit before the change of operating capital | --0 | 14.31%7.35B | --0 | 6.79%6.43B | --0 | -10.23%6.02B | --0 | 17.93%6.71B | --0 | 51.07%5.69B |
| Change of operating capital | ||||||||||
| Inventory (increase) decrease | ---- | -580.47%-391.1M | ---- | 74.05%-57.48M | ---- | 50.73%-221.45M | ---- | -339.93%-449.44M | ---- | -331.31%-102.16M |
| Accounts receivable (increase)decrease | ---- | 70.90%-470.06M | ---- | -975.26%-1.62B | ---- | -176.52%-150.22M | ---- | 145.00%196.31M | ---- | -686.48%-436.21M |
| Accounts payable increase (decrease) | ---- | 29.49%1.11B | ---- | 19.61%857.86M | ---- | 217.31%717.19M | ---- | -81.97%226.02M | ---- | 123.62%1.25B |
| prepayments (increase)decrease | ---- | -226.96%-519.9M | ---- | 293.39%409.49M | ---- | -4.09%-211.74M | ---- | 56.41%-203.41M | ---- | -411.76%-466.65M |
| Cash from business operations | --0 | 17.47%7.16B | --0 | -3.05%6.09B | --0 | -2.21%6.28B | --0 | 8.32%6.43B | --0 | 41.37%5.93B |
| Other taxs | ---- | -22.76%-892.09M | ---- | 24.24%-726.72M | ---- | 12.97%-959.18M | ---- | -31.43%-1.1B | ---- | -80.61%-838.55M |
| Special items of business | ---- | 12.64%74.62M | ---- | -48.06%66.25M | ---- | 343.93%127.55M | ---- | -849.67%-52.29M | ---- | -113.66%-5.51M |
| Net cash from operations | -32.36%2.67B | 16.75%6.27B | 69.08%3.95B | 0.77%5.37B | 50.14%2.34B | 0.01%5.33B | -55.65%1.56B | 4.52%5.32B | 70.38%3.51B | 36.49%5.09B |
| Cash flow from investment activities | ||||||||||
| Interest received - investment | ---- | 24.30%201.44M | ---- | -16.47%162.06M | ---- | -21.25%194M | ---- | 68.89%246.36M | ---- | 121.21%145.87M |
| Dividend received - investment | ---- | -77.76%893.45M | ---- | 46,383.92%4.02B | ---- | 122.33%8.64M | ---- | -68.02%3.89M | ---- | -98.22%12.16M |
| Loan receivable (increase) decrease | ---- | 46.54%-17.21M | ---- | 39.71%-32.19M | ---- | 13.97%-53.39M | ---- | -1,873.17%-62.06M | ---- | 200.00%3.5M |
| Decrease in deposits (increase) | -5.42%-2.74B | -62.20%-3.82B | -510.08%-2.6B | -6.87%-2.36B | --634.89M | -162.80%-2.2B | ---- | -1,623.13%-838.99M | ---- | 123.68%55.08M |
| Sale of fixed assets | ---- | -78.90%27.89M | ---- | 30.69%132.2M | ---- | 60.31%101.15M | ---- | 267.66%63.09M | ---- | -2.85%17.16M |
| Purchase of fixed assets | -20.25%-753.91M | 27.47%-1.24B | -7.06%-626.97M | -20.35%-1.71B | ---585.61M | 1.74%-1.42B | ---- | 6.48%-1.45B | ---- | -46.48%-1.55B |
| Purchase of intangible assets | ---- | -98.10%-302.94M | ---- | 57.99%-152.92M | ---- | -27.95%-363.99M | ---- | -123.93%-284.48M | ---- | -151.70%-127.04M |
| Sale of subsidiaries | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 18.88%170M | ---- | 30.00%143M |
| Acquisition of subsidiaries | --458K | ---- | ---- | ---798.75M | ---757.16M | ---- | ---- | -137.00%-391.67M | ---- | 2,375.62%1.06B |
| Recovery of cash from investments | ---- | -18.02%412.89M | ---- | 65.28%503.67M | ---- | -5.53%304.74M | ---- | -15.84%322.58M | ---- | 44.06%383.31M |
| Cash on investment | 88.60%-384.45M | 70.64%-782.11M | -116.05%-3.37B | 70.73%-2.66B | ---1.56B | -890.78%-9.1B | ---- | -292.36%-918.71M | ---- | 131.20%477.6M |
| Other items in the investment business | -131.32%-191.99M | 45.20%561.22M | 134.29%612.94M | -91.77%386.51M | ---1.79B | 785.50%4.69B | ---- | 44.56%-684.88M | ---- | -907.41%-1.24B |
| Net cash from investment operations | 31.97%-4.07B | -61.80%-4.07B | -47.68%-5.99B | 67.93%-2.52B | -164.48%-4.06B | -105.15%-7.85B | 30.61%-1.53B | -520.73%-3.82B | -549.37%-2.21B | 62.13%-616.1M |
| Net cash before financing | 31.22%-1.4B | -23.01%2.19B | -18.62%-2.04B | 213.10%2.85B | -7,932.88%-1.72B | -267.98%-2.52B | -98.31%21.96M | -66.50%1.5B | -49.14%1.3B | 112.70%4.48B |
| Cash flow from financing activities | ||||||||||
| New borrowing | 41.55%10.93B | 593.65%9.75B | 1,310.46%7.72B | -8.57%1.41B | --547.29M | -81.68%1.54B | ---- | 2,006.73%8.39B | ---- | -42.45%398.48M |
| Refund | -55.11%-10.2B | -174.02%-7.03B | -716.55%-6.58B | -45.80%-2.57B | ---805.6M | 44.93%-1.76B | ---- | -3,306.59%-3.2B | ---- | 88.12%-93.82M |
| Interest paid - financing | ---- | -89.02%-339.52M | ---- | 16.57%-179.62M | ---- | 36.60%-215.31M | ---- | -121.58%-339.6M | ---- | -96.63%-153.26M |
| Dividends paid - financing | -494.20%-546.05M | -119.42%-2.97B | 70.83%-91.9M | 50.22%-1.35B | ---315.04M | -34.33%-2.71B | ---- | -15.33%-2.02B | ---- | -40.49%-1.75B |
| Issuance expenses and redemption of securities expenses | -65.88%-3.9B | -327.88%-2.54B | ---2.35B | -203.81%-593.56M | ---- | -509.59%-195.37M | ---- | 94.70%-32.05M | ---- | ---604.42M |
| Other items of the financing business | -101.50%-317.28M | -206.27%-63.18M | 16.39%-157.46M | -98.93%59.46M | ---188.34M | 99,401.26%5.58B | ---- | -120.39%-5.62M | ---- | 110.00%27.56M |
| Net cash from financing operations | -176.76%-4.04B | 1.21%-3.19B | -91.75%-1.46B | -244.42%-3.23B | -114.90%-761.69M | -20.27%2.23B | 513.25%5.11B | 228.61%2.8B | 7.63%-1.24B | -28.25%-2.18B |
| Effect of rate | 358.23%84.83M | 107.28%47.32M | 71.12%-32.85M | -332.03%-649.71M | -17.28%-113.77M | 194.59%280.02M | -394.28%-97M | -60.80%95.05M | -75.52%32.96M | 211.33%242.47M |
| Net Cash | -55.54%-5.45B | -164.59%-992.05M | -41.06%-3.5B | -30.63%-374.95M | -148.36%-2.48B | -106.67%-287.03M | 8,370.28%5.13B | 86.96%4.3B | -95.00%60.59M | 464.67%2.3B |
| Begining period cash | -9.84%8.65B | -9.64%9.6B | -9.64%9.6B | -0.07%10.62B | -0.07%10.62B | 70.51%10.63B | 70.51%10.63B | 68.88%6.24B | 68.88%6.24B | 5.41%3.69B |
| Cash at the end | -45.69%3.29B | -9.84%8.65B | -24.45%6.07B | -9.64%9.6B | -48.76%8.03B | -0.07%10.62B | 147.55%15.67B | 70.51%10.63B | 25.61%6.33B | 68.88%6.24B |
| Cash balance analysis | ||||||||||
| Cash and bank balance | -33.01%2.82B | ---- | -24.46%4.21B | ---- | -38.23%5.58B | ---- | 111.68%9.03B | ---- | 69.77%4.26B | ---- |
| Cash and cash equivalent balance | -33.01%2.82B | --0 | -24.46%4.21B | --0 | -38.23%5.58B | --0 | 111.68%9.03B | --0 | 69.77%4.26B | --0 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg